It appears that lenvatinib is a multikinase inhibitor that particularly works on VEGFR kinases, so a sort of super-Avastin. It is being combined with pembrolizumab (Keytruda) for several cancers and just got FDA approval for endometrial cancer, according to Dr. Google. The LEAP abstract claims lenvatinib increases the "good" white cells (the ones that attack) and decreases the "traitor" ones (the ones that tend to protect the tumor) since VEGF, among its other activities, seems to affect the immune system.
They would be comparing it with a more standard third-line treatment in this case (Lonsurf+regorafenib).
D/H Dx 10/2019 RC age 61
Clinical T4bN2M1a (common iliac and para-aortic lymph nodes)
MSS KRAS G12D
CRT 11/19-1/20 FOLFOX 3/20-7/20
Pelvic exenteration w/LAR 8/20
ypT4bN0Mx G3 0/14 nodes LVI not seen PNI-
CEA 10/19:20, 1/20-11/20:1.6, 4.3, 3.4, 2.7, 2/21:9.0 3/21:18,40 4/21:28,19, 5/21:13.3,8.6
PET 3/21 recurrence in distal nodes, L5 vertebra, pelvis